What's new? Log in Free sign up

Exicure (XCUR)

Company Profile

Company profile

Ticker

XCUR

Exchange

Website

www.exicuretx.com

CEO

Mr. Paul Kang

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

Max-1 Acquisition Corp

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Exicure Operating Company ...

XCUR stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Entry into a Material Definitive Agreement

Financial Statements and Exhibits

Entry into a Material Definitive Agreement

Departure of Directors or Certain Officers

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Entry into a Material Definitive Agreement

Definitive proxy

2 Dec 24

Latest ownership filings

View all

Initial statement of insider ownership

SANGSANGIN INVESTMENT & SECURITIES CO., LTD.

HiTron Systems Inc.

Initial statement of insider ownership

Change in insider ownership

Financial summary

Financial statements Chart XCUR financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	951.00 k	951.00 k	951.00 k	951.00 k	951.00 k	951.00 k
Cash burn (monthly)	149.67 k	97.58 k	857.33 k	511.75 k	149.67 k	240.08 k
Cash used (since last report)	760.49 k	495.85 k	4.36 mm	2.60 mm	760.49 k	1.22 mm
Cash remaining	190.51 k	455.15 k	-3.41 mm	-1.65 mm	190.51 k	-268.92 k
Runway (months of cash)	1.3	4.7	-4.0	-3.2	1.3	-1.1

Beta Read what these cash burn values mean

Financial data from Exicure earnings reports.

Institutional ownership, Q3 2024

XCUR institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	8	16	-50.0%
Opened positions	3	1	+200.0%
Closed positions	11	6	+83.3%
Increased positions	0	2	EXIT
Reduced positions	4	4	–

13F shares	Current	Prev Q	Change
Total value	975.13 mm	156.69 mm	+522.3%
Total shares	5.76 mm	8.38 mm	-31.3%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Gates Ventures	4.84 mm	$1.17 mm	0.0%
CBI USA	849.22 k	$1.92 mm	-72.2%
CG The Carlyle Group Inc.	56.33 k	$971.64 mm	-80.0%
HRT Financial	14.48 k	$50.00 k	NEW
Advisor	59.00	$203.00 k	-79.6%
BlackRock	35.00	$121.00 k	NEW
BNP Paribas Arbitrage	4.00	$14.00 k	NEW
JPM JPMorgan Chase & Co.	2.00	$7.00 k	-80.0%
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
CBI USA	849.22 k	-2.21 mm	-72.2%
CG The Carlyle Group Inc.	56.33 k	-225.31 k	-80.0%
Geode Capital Management	0.00	-56.52 k	EXIT
Susquehanna International	0.00	-46.00 k	EXIT
Vanguard	0.00	-40.09 k	EXIT
UBS UBS	0.00	-17.31 k	EXIT
Renaissance Technologies	0.00	-14.90 k	EXIT
HRT Financial	14.48 k	+14.48 k	NEW
Millennium Management	0.00	-12.03 k	EXIT
Tower Research Capital	0.00	-7.18 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

XCUR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Feb 25	Josh Miller	Common Stock	Payment of exercise	Dispose F	No	No	10.03	9	90.27	333

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Exicure Enters Share Purchase Agreement With GPCR Therapeutics

Press releases

From Benzinga Pro

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. (NASDAQ:XCUR, "the Company", "Exicure")), today announced that on January 19, 2025, Exicure Inc. ("the Company") entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

Exicure, Inc. (NASDAQ:XCUR, "Exicure", "the Company")), has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. ("GPCR Therapeutics") on December 24, 2024, aimed at the acquisition

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. (NASDAQ:XCUR, "the Company", "Exicure")), today announced that in connection with the change of control transaction approved by the stockholders at the Special Meeting of the Stockholders on December 17,

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.